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Abstract
Introduction: Pheochromocytomas are benign or malignant neuroendocrine tumours. The unsatisfactory efficacy of the traditional 
therapeutic methods for patients with metastatic disease results in a continuing search for more effective and targeted agents. Due to the 
increased vascularisation of these tumours, inhibitors of angiogenesis could be potentially a new group of drugs in pheochromocytoma/ 
/paraganglioma therapy.
Material and methods: The aim of this study was to evaluate the influence of angiomodulators: VEGF (vascular endothelial growth factor) 
and five endogenous and exogenous antiangiogenic compounds (endostatin; IFN-a [interferon alpha]; rapamycin — mTOR [mammalian 
target of rapamycin] inhibitor; JV1-36 and SU5416 (semaxinib]) on the growth of rat pheochromocytoma PC12 cell line.
Results: IFNa (105 U/mL) strongly inhibited PC12 growth in a 72 h culture, increasing apoptosis and arresting the cell cycle. Rapamycin 
in a wide range of concentrations (10-5 to 10-8 M) induced a slight inhibitory effect on PC12 viability and decreased cell proliferation at the 
concentration of 10-5 M. VEGF, endostatin and JV1-36 did not influence the growth of PC12.
Conclusions: The study has shown for the first time that IFN-a inhibited the growth of pheochromocytoma PC12 line and confirmed the 
inhibitory action of rapamycin on these cells. The results suggest that IFN-a and mTOR inhibitors could be potentially effective in the 
therapy of malignant pheochromocytoma, and encourage further study in this field.
(Endokrynol Pol 2013; 64 (5): 368–374)
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Streszczenie
Wstęp: Guzy chromochłonne (pheochromocytoma/paraganglioma) należą do łagodnych lub złośliwych nowotworów neuroendokrynnych. 
Wobec niezadowalającej skuteczności standardowych sposobów leczenia pacjentów z rozsianą postacią choroby, wciąż poszukuje się nowych 
metod terapii, w tym możliwości skutecznego leczenia celowanego. W związku ze wzmożonym unaczynieniem tych nowotworów, preparaty 
o działaniu antyangiogennym mogą potencjalnie stanowić nową grupę leków stosowanych w leczeniu pheochromocytoma/paraganglioma.
Materiał i metody: W badaniu oceniano wpływ różnych angiomodulatorów: VEGF (naczyniowo-środbłonkowy czynnik wzrostu) oraz 
pięciu endo- i egzogennych czynników antyangiogennych (endostatyna; IFN-a [interferon alfa]; rapamycyna — inhibitor szlaku mTOR 
[mammalian target of rapamycin]; JV1-36 and SU5416 [semaxinib]) na wzrost szczurzej linii pheochromocytoma PC12.
Wyniki: IFN-a (105 U/mL) silnie hamował wzrost komórek PC12 w hodowli 72 h, nasilając apoptozę i hamując cykl komórkowy. Rapamy-
cyna w szerokim zakresie stężeń (10-5 to 10-8 M) nieznacznie zmniejszała żywotność komórek PC12, a w stężeniu 10-5 M także hamowała 
ich proliferację. VEGF, endostatyna oraz JV1-36 nie wpływały na wzrost lini PC12.
Wnioski: W badaniu po raz pierwszy wykazano, że IFN-a hamuje wzrost linii komórkowej pheochromocytoma PC12, a także potwier-
dzono hamujący wpływ rapamycyny wobec tej linii komórkowej. Uzyskane wyniki sugerują zatem, że IFN-a oraz inhibitory szlaku 
mTOR mogą być potencjalnie skuteczne w leczeniu złośliwych postaci guzów chromochłonnych i zachęcają do dalszych badań w tym 
kierunku. (Endokrynol Pol 2013; 64 (5): 368–374)
Słowa kluczowe: pheochromocytoma, interferon alpha, rapamycyna, czynniki antyangiogenne, linia PC12
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Introduction
Pheochromocytoma and paraganglioma are numbered 
among neuroendocrine tumours (NETs). They can occur 
sporadically or as a part of familial syndrome, and can 
be benign or malignant tumours [1]. Gene mutations 
often observed in these tumours are part of two distinct 
molecular pathways: cluster 1 (mutations of VHL, SDHB 
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and SDHD) leading to overexpression of angiogenic fac-
tors; and cluster 2 (mutations of RET, NF1, TMEM127, and 
MAX) associated with abnormal activation of kinase sig-
nalling pathways such as PI3kinase/AKT, mTOR1/p70s6K 
and RAS/RAF/ERK, leading to abnormal cell growth and 
lack of apoptosis capacity* [2]. These signalling altera-
tions promote tumourigenesis, as hyperactivity of mTOR 
pathway is a well established factor leading to different 
neoplasms [3] and increased angiogenesis has been shown 
to be associated with the development of metastases, poor 
prognosis and reduced survival in many tumours [4]. The 
invasiveness of pheochromocytoma also correlated with 
the number of tumour blood vessels and increased VEGF 
(vascular endothelial growth factor) immunoreactiv-
ity [5]. The importance of VEGF for the angiogenesis of 
pheochromocytomas has also been demonstrated in in 
vitro studies [6]. Moreover, malignant pheochromocyto-
mas are characterised by increased expression of several 
other proangiogenic factors [7]. The traditional therapeutic 
methods (surgery, 131I-MIBG (metaiodobenzylguanidine), 
chemotherapy) for patients with metastatic pheochromo-
cytoma/paraganglioma are limited and often ineffective 
[2, 8, 9]. Thus, better understanding of specific molecular 
pathways alteration in the development of pheochromo-
cytoma/paraganglioma might lead to molecular-targeted 
therapy, using antiangiogenic agents and mTOR inhibitors.
Therefore, this paper aims to study the direct influ-
ence of proangiogenic (VEGF) and antiangiogenic (ra-
pamycin, interferon alpha, endostatin, JV1-36, SU5416) 
compounds on the growth of rat pheochromocytoma 
PC12 cell line. The PC12 cell, a clonal cell line derived 
from a pheochromocytoma of the rat adrenal medulla, 
seems to be an excellent experimental model for study-
ing the influence of exogenous angiogenic modulators 
on the growth and functional activity of neuroendo-
crine adrenal chromaffin cells.
Rapamycin, a naturally occurring macrolide an-
tibiotic, was the first known inhibitor of PI3K/AKT/ 
/mTOR-pathway, which was initially discovered as an 
antifungal drug and immunosuppressive agent. The 
antiangiogenic and antitumour activity of rapamycin 
was found later [3, 10] and gave rise to the use of mTOR 
inhibition in cancer treatment, which has proved to be 
effective in a number of neoplasms [3], including neu-
roendocrine tumours [11]. In 2011, the FDA (Food and 
Drug Administration) approved an mTOR inhibitor, 
everolimus, for the treatment of progressive pancreatic 
neuroendocrine tumours (PNETs) (NCI; http://www.
cancer.gov/cancertopics/druginfo/fda-everolimus). 
JV1-36 belongs to GHRH (growth hormone releasing 
hormone) antagonists, which have been shown to exert 
antiproliferative effects in different tumours. The mecha-
nism of GHRH antagonist action is complex and apart from 
inhibition of IGFs (insulin-like growth factors) production, 
the suppression of VEGF and bFGF (basic fibroblast growth 
factor) expression in neoplasms is suggested [12].
SU5416 (semaxinib), a 3-substituted indolinone 
compound, was the first VEGFR (vascular endothelial 
growth factor receptor) tyrosine kinase inhibitor tested 
clinically as antiangiogenic treatment in cancer [13].
Endostatin is a proteolytic fragment of collagen XVII. 
It is an endogenous inhibitor of angiogenesis which 
also exerts an antineoplastic action [14, 15]. Although 
endostatin suppressed the growth of pancreatic neu-
roendocrine tumour in transgenic RT2 (RIP-Tag2) mice 
[16], the clinical study did not confirm the effectiveness 
of endostatin in PNET treatment [17].
Interferon alpha (IFN-a) is a pleiotropic cytokine with 
proven antitumour activity. The antineoplastic effect of 
IFN-a is triggered in direct (prolongation of the cell cycle 
time and enhancement of apoptosis in malignant cells), 
and indirect (interaction with other cytokines, immuno-
modulatory and antiangiogenic influence), mechanisms 
[18). IFN-a as an angiogenesis inhibitor was first reported 
in 1980 [19] and then was confirmed by other authors [18, 
20]. The clinical use of IFN-a includes treatment of renal 
cell carcinoma, melanoma, neuroendocrine tumours and 
some other neoplasms [18].
Material and methods
Cell line and culture condition
The rat pheochromocytoma cell line PC12 obtained from 
the American Type Culture Collection (ATCC) was used 
in the experiments. The cells were routinely grown as a 
monolayer in a humidified incubator at 37○C with 5% CO2 
in F12-K medium (ATCC), supplemented with 100 U/mL 
penicillin and 100 μg/mL streptomycin solution (Sigma), 
15% horse serum (ATCC) and 2.5% fetal bovine serum 
(Biochrom). The cells were passaged every seven days 
with 0.05% trypsin/0.02% EDTA (Trypsin-EDTA, Sigma) 
and the medium was changed every 3–4 days.
Substances
The following substances were used in the experiments: 
mouse IFN-a (Sigma), rapamycin (Sigma), JV1-36 (Ba-
chem), SU5416 (Sigma), mouse endostatin (Sigma), 
mouse VEGF (Sigma).
*(VHL — von Hippel Lindau, SDHB and SDHD — subunits B and D of the succinate dehydrogenase (SDH); RET — rearranged during 
transfection; NF1 —Neurofibromatosis type I; TMEM127 — transmembrane protein 127; MAX — MYC associated factor X; PI3kinase/AKT 
— phosphatidylinositol 3-kinase/protein kinase B; mTOR1/p70s6K — mammalian target of rapamycin/p70 ribosomal S6 kinase; RAS/RAF/
ERK — cascade of extracellular signal-regulated kinase)
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IFN-a, JV1-36, endostatin and VEGF were diluted in 
serum free culture medium and added to the appropriate 
wells at the final concentrations as indicated in figures. 
The control group in these experiments received medium.
Rapamycin was dissolved in 96% ethanol and se-
rum free culture medium (5% of 96% ethanol in stock 
solution) and added to the appropriate wells at the 
final concentrations as indicated in figures. The ap-
propriate volume of serum free culture medium and 
96% ethanol at the final concentration identical with 
the solvent concentration in 10-5M group was added 
to the control wells.
SU5416 was dissolved in DMSO and serum free 
culture medium (10% of DMSO in stock solution) and 
added to the appropriate wells at the final concentra-
tions as indicated in figures. The appropriate volume of 
serum free culture medium and DMSO at the final con-
centration identical with the solvent concentration in 
every examined group was added to the control wells. 
The action of all the agents in a wide range of con-
centrations was determined using an MTT colorimetric 
assay. Following this, based on the results of the MTT 
study, some concentrations of the substances were 
further assessed using the BrdU incorporation method, 
cell cycle analysis and apoptosis examination. However, 
the MTT method was not used to estimate the influence 
of SU5416 on PC12 cell growth because of the potential 
interference of this yellow-dyeing compound with the 
manufacturer’s procedures.
Cell viability/cytotoxicity study/Mosmann 
method
The MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide) colorimetric assay was used as an 
indicator of cell viability/cytotoxicity. PC12 cells were 
seeded at a density of 10 x 103 cells/well into 96-well 
microplates in 180 μL/well of complete culture medium. 
After preincubation (24 h), the cells were cultured for a 
further 72 h in the presence of various concentrations of 
the examined substances (20 μL: IFN-a, rapamycin, JV1-36, 
endostatin, VEGF). Cell viability was assessed using the 
EZ4U assay kit (The 4th Generation Non Radioactive Cell 
Proliferation & Cytotoxity Assay, Biomedica Gesellschaft 
mbH, Biomedica Gruppe, Austria) according to the manu-
facturer’s instructions. The optical density (OD) of each 
sample was measured by a microplate reader at 450 nm.
Cell proliferation study
Colorimetric immunoassay based on the measurement 
of 5-bromo-2’-deoxyuridine (BrdU) incorporation dur-
ing DNA synthesis was used for the quantification of 
PC12 cell proliferation. PC12 cells were seeded at a 
density of 10 x 103 cells/well into 96-well microplates 
in 90 μL/well of complete culture medium. After pre-
incubation (24 h), the cells were cultured for a further 
72 h in the presence of various concentrations of the 
examined substances (10 μL: IFN-a, rapamycin, JV1-36, 
SU5416, endostatin, VEGF). Cell proliferation was as-
sessed using the BrdU assay (Cell proliferation ELISA, 
BrdU, Roche) following the producer’s instructions. 
The optical density (OD) of each sample was measured 
by a microplate reader at 450 nm.
Cell cycle analysis 
PC12 cells were seeded at a density of 3 x 105 cells/well 
into six-well microplates in 1,350 μL/well of complete 
culture medium. After preincubation (24 h), the cells 
were cultured for a further 72 h in the presence of various 
concentrations of the examined substances (150 μL: IFN-a, 
rapamycin). After 72 h of incubation, cells were harvested 
by gentle trypsynisation, centrifuged, resuspended in 100 
μL of phosphate-buffered calcium and magnesium free 
saline (PBS), and fixed in 70% ice-cold ethanol. After 
centrifugation at 4°C, the cells were finally suspended in 
PBS containing 75 μmol/dm3 propidium iodide (PI) and 
50 IU Kunitz/mL of DNase-free RNase (Sigma Aldrich). 
After 30 min of incubation, the cell counts were taken 
with an LSR II Flow Cytometer (Becton Dickinson). The 
percentage of cells in G1, S and G2/M phases of the cell 
cycle and the percentage of cells undergoing apoptosis 
were determined with FlowJo analytical software.
Apoptosis induction assay
PC12 cells were seeded at a density of 3 x 105 cells/well 
into six-well microplates (NUNC, Denmark) in 1,350 μL/ 
/well of complete culture medium. After preincubation (24 
h), the cells were cultured for a further 72 h in the pres-
ence of various concentrations of the examined substances 
(150 μL: IFN-a, rapamycin). Apoptosis was measured 
using flow cytometry to quantify the levels of detectable 
phosphatidylserine on the outer membranes of apoptotic 
cells. Fluorescein isothiocyanate (FITC) Annexin-V Apop-
tosis Detection Kit (Becton Dickinson, San Jose, CA, USA) 
was used for the differentiation of apoptotic and necrotic 
cells. Briefly, after 72 h of incubation, cells were harvested 
by gentle trypsynisation and washed with cold PBS. The 
cells were resuspended in 1 mL of 1× binding buffer. One 
hundred microlitres were transferred to a 5 mL culture 
tube, and 5 μL of Annexin V-FITC and 5 μL of propidium 
iodide (PI) were added. Cells were vortexed and incubated 
for 15 min in the dark at room temperature. Next, 400 μL 
of 1 × binding buffer was added to each tube. Flow cyto-
metric analysis was performed immediately after staining. 
Annexin-V/PI fluorescence was analysed for each sample; 
the fluorescence of 10,000 cells was gated and counted using 
FlowJo software. Early apoptotic cells were identified as PI 
negative, FITC Annexin V positive, whereas cells in the late 
stages of apoptosis were positive for both annexin V and PI.
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Statistical analysis
The results of cell viability and cell proliferation are ex-
pressed as the average percentage of the optical density 
(OD) of the control groups. Comparisons of individual 
groups were evaluated by analysis of variance (one-
way ANOVA) following LSD test (Least Significant 
Difference). Differences were considered significant if 
p < 0.05. The results of cell cycle and apoptosis analysis 
are expressed as mean percentage of number of cells 
in G1, S and G2 phases or as percentage of apoptotic 
cells, respectively.
Results
IFN-a at the highest concentration of 105 U/mL 
strongly inhibited PC12 growth in 72 h culture, up 
to 50% of the control group in MTT method (Fig. 1) 
and up to 47% of the control group in BrdU incorpo-
ration method (Fig. 1). At this concentration, IFN-a 
increased apoptosis up to 17.1% of PC12 cell (2.7% 
cells in early apoptosis and 14.4% cells in late apopto-
sis) v. 6.1% of cells in the control group (1.7% cells in 
early apoptosis and 4.4% cells in late apoptosis) (Fig. 
3 and Table I). IFN-a at the concentration of 105 U/
mL induced G0/G1 phase arrest (Fig. 4 and Table II).
Rapamycin at many concentrations (10-5 to 10-8 M) 
slightly inhibited PC12 cell viability (up to 86–93% of the 
control group) (Fig. 2). However, in the cell proliferation 
assay, only the highest concentration of rapamycin (10-5 
M) was shown to be active (90% of the control group) 
(Fig. 2). Rapamycin did not induce apoptosis or influ-
ence cell cycle in a statistically dependent manner (Figs. 
3–4, Tables I-II).
SU5416 at the concentration of 10-5 M inhibited BrdU 
incorporation in PC12 cells up to 86% of the control 
group (Fig. 5).
Table II. The effect of interferon alpha (IFN 105 U/mL) and 
rapamycin (RAP 10-5 M) on the cell cycle of PC12 cells in 
72 h culture
Tabela II. Wpływ interferonu a (IFN 105 U/mL) i rapamycyny 
(RAP 10-5 M) na cykl komórkowy linii guza chromochłonnego 
PC12 w hodowli 72 h
Control RAP IFN
G1 63.5% 66.4% 72.3%
S 21.7% 18.3% 8.9%
G2 12.6% 15.5% 19.1%
Table I. The effect of interferon alpha (IFN 105 U/mL) and 
rapamycin (RAP 10-5 M) on the apoptosis of PC12 cells in 
72 h culture
Tabela I. Wpływ interferonu a (IFN 105 U/mL) i rapamycyny 
(RAP 10-5 M) na apoptozę komórek linii guza chromochłonnego 
PC12 w hodowli 72 h
Viability Apoptosis Necrosis
Control 91.7% 6.1% 2.1%
RAP 88.8% 8.0% 3.2%
IFN 79.3% 17.1% 3.6%
Figure 1. The effect of interferon alpha (IFN) on the growth 
of the PC12 pheochromocytoma cell line assessed by Mosmann 
and BrDU incorporation methods in 72 h culture. X ± S.E.M., 
*p < 0.05 v. control
Rycina 1. Wpływ interferonu a (IFN) na wzrost komórek linii 
guza chromochłonnego PC12 oceniany metodą Mosmanna 
i wbudowywania BrDU w hodowli 72 h. X ± S.E.M., *p < 0.05 
v. kontrola
Figure 2. The effect of rapamycin (Rap) on the growth of the 
PC12 pheochromocytoma cell line assessed by Mosmann and 
BrDU incorporation methods in 72 h culture. X ± S.E.M., 
*p < 0.05 v. control
Rycina 2. Wpływ rapamycyny (Rap) na wzrost komórek linii 
guza chromochłonnego PC12 oceniany metodą Mosmanna 
i wbudowywania BrDU w hodowli 72 h. X ± S.E.M., *p < 0.05 
v. kontrola
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From all studied concentrations of JV1-36 (10-5, 10-6, 
10-7, 10-8, 10-9, 10-10 M), only the highest concentration 
slightly (up to 92% of the control group), but statisti-
cally insignificantly, inhibited the growth of PC12 cells 
in Mosmann method (data not shown).
Endostatin (at the concentrations of 30; 15; 7.5; 3.75; 
1.875; 0.9375 μg/mL) and VEGF (at the concentrations of 
100; 50; 25; 12.5; 6.25; 3.125; 1.5625 ng/mL) did not evoke 
inhibition of PC12 growth (data not shown).
Discussion
This paper aims to study the influence of interferon 
a mTOR inhibitor (rapamycin), VEGF receptor antago-
nist (SU5416), GHRH receptor antagonist (JV1-36) and 
endostatin on pheochromocytoma growth, as these 
factors have been shown to reduce vascularisation and 
cell proliferation of different solid tumours. Moreover, 
the presence of specific molecular pathway alteration 
in pheochromocytoma/paraganglioma additionally 
suggests the potential effectiveness of antiangiogenic 
agents and mTOR inhibitors in these tumours. Since all 
efforts to establish the cell lines derived from human 
pheochromocytomas and paragangliomas have been 
unsuccessful (the cells survive but do not proliferate 
in vitro) [21], a rat pheochromocytoma PC12 cell line 
was chosen for our studies. PC12 line has been used for 
studying the mechanism of actions of different growth 
Figure 3. The effect of interferon alpha (IFN 105 U/mL) and rapamycin (RAP 10-5 M) on the apoptosis of PC12 cells in 72 h culture 
Rycina 3. Wpływ interferonu a (IFN 105 U/mL) i rapamycyny (RAP 10-5 M) na apoptozę komórek linii guza chromochłonnego PC12 
w hodowli 72 h
Figure 4. The effect of interferon alpha (IFN 105 U/mL) and 
rapamycin (RAP 10-5 M) on cell cycle phase distribution of PC12 
cells in 72 h culture
Rycina 4. Wpływ interferonu a (IFN 105 U/mL) i rapamycyny 
(RAP 10-5 M) na cykl komórkowy linii guza chromochłonnego 
PC12 w hodowli 72 h
Figure 5. The effect of SU5416 on the growth of the PC12 
pheochromocytoma cell line assessed by BrDU incorporation 
method in 72h culture. X ± S.E.M., *p < 0.05 vs. control
Rycina 5. Wpływ SU5416 na wzrost komórek linii guza 
chromochłonnego PC12 oceniany metodą wbudowywania BrDU 
w hodowli 72 h. X ± S.E.M., *p < 0.05 v. kontrola
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and trophic factors for many years. It was revealed that 
NGF (nerve growth factor) and bFGF caused differen-
tiation (neurite outgrowth), whereas EGF (epidermal 
growth factor) stimulated the proliferation of PC12 cells. 
These effects were dependent on the MAPK (mitogen 
activated protein kinases) and/or mTOR signalling 
pathways [22, 23]. PC12 cells have also been shown 
to synthesise several growth factors, e.g. NGF, bFGF, 
VEGF [5, 24, 25], as well as to possess NGF, EGF, FGF 
and VEGF receptors [26– 28].
Although IFN-a is an alternative line treatment in 
some neuroendocrine tumours [29], it has not been 
used in pheochromocytoma therapy so far [2, 8, 9]. 
The influence of IFN-a on pheochromocytoma has 
not been estimated in experimental conditions either. 
Thus, we have shown for the first time that IFN-a at 
the concentration of 105 U/mL caused strong pheo-
chromocytoma PC12 cell growth inhibition, inducing 
apoptosis as well as arresting the cell cycle in G0/G1 
phase. The results confirmed the complex action of 
IFN-a, which potentially included prolongation of the 
cell cycle time [30], enhancement of apoptosis [31] and 
modulation of expression of FGF-2 [32] and VEGF in 
different malignant cells [33].
Similarly, the slight inhibitory effect of rapamycin 
(10-5–10-8 M) on PC12 cell growth observed in our study 
was probably also evoked by multitargeted activity of 
this drug. Rapamycin, as an mTOR inhibitor, has been 
shown to block the signalling pathways for many 
growth factors [3], including those whose receptors 
are expressed on PC12 cells (VEGF, bFGF, NGF, EGF). 
Our results remain in agreement with other studies, 
in which rapamycin at concentrations of 10-5–10-9 M 
inhibited PC12 cell proliferation in 48 h culture [34]. 
These facts encourage further studies in this field and 
suggest that mTOR inhibitors could be not only an alterna-
tive treatment in PNETs (everolimus - approved by FDA), 
but possibly also in malignant pheochromocytoma [35].
The application of VEGF receptor inhibitors in the 
therapy of different neoplasms gave divergent results. 
Although the administration of SU5416 resulted in re-
duction of the growth of different xenografted tumours 
in mice, it did not inhibit the growth of a variety of 
neoplastic cells in vitro [36]. In our study, SU5416 at the 
concentration of 10-5 M slightly inhibited the proliferation 
of PC12 cells. Similarly, sunitinib (a derivative compound 
of SU5416) markedly induced apoptosis of PC12 cells, ini-
tially exerting its apoptotic effect through the inhibition 
of VEGFR-2, followed by reduction of its downstream 
effectors (including AKT/mTOR/S6K1) and leading to 
inhibition of the antiapoptotic molecule Bcl-2 and activa-
tion of the proapoptotic molecule BAD [37]. Moreover, 
sunitinib also gave encouraging results in preliminary 
studies in patients with malignant pheochromocytoma 
[8]. Thus, our results together with other studies suggest 
that tyrosine kinase inhibitors are a promising group of 
agents in the therapy of these tumours.
It is interesting that despite the expression of VEGF 
receptors on PC12 cells, VEGF used in a wide range of 
concentrations did not affect PC12 cell growth in our 
study. This is in accordance with the study of other au-
thors, in which no functional effects of VEGF on PC12 
cell proliferation or on neurite formation were observed 
[28]. On the other hand, it has been confirmed that an-
giogenesis and tumour size in xenotransplanted PC12 
cells in mice are VEGF-dependent and inhibited by 
treatment of anti-VEGF antibodies [5]. These facts sug-
gest that VEGF did not affect PC12 cell growth directly, 
but indirectly contributed to the growth of xenografted 
PC12 tumour in vivo by stimulation of angiogenesis. 
These observations can also explain the fact that in our 
experiments endostatin, which acts mainly by blocking 
VEGF/VEGFR signalling [38], does not have any effect 
on the growth of PC12 cell line. Moreover, other authors 
did not show a direct binding of endostatin to the PC12 
cell surface [28, 39], suggesting the absence of receptors 
for endostatin in this cell line. 
Although GHRHR (GHRH receptor) has been 
shown to be present in human benign (higher expres-
sion) and malignant (lower expression) pheochromocy-
tomas, it has not been demonstrated in PC12 cells [40]. 
This could explain the lack of antiproliferative activity 
of JV1-36 in our experiments. However, the effectiveness 
of GHRH inhibitors is still worthy of being assessed in 
different pheochromocytoma/paraganglioma models.
In conclusion, although PC12 pheochromocytoma 
cells express receptors which could be potentially sensi-
tive to antiangiogenic treatment, many agents evaluated 
in this study did not act directly as anti-mitogenic factors 
on PC12 cell growth in vitro. IFN-a mTOR and tyrosine 
kinase inhibitors as multitarget drugs turn out to be more 
effective than agents selectively blocking only pathways 
typical for angiogenic factors, and they seem to be drugs 
of sufficient interest to justify further studies.
Thus, considering the unsatisfactory efficacy of the 
traditional therapeutic methods in patients with meta-
static pheochromocytoma, the results of our preclinical 
studies indicate that antiangiogenic agents and mTOR 
inhibitors might comprise a new therapeutic option in 
clinical use.
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